Market anticipation grows over imminent competition between ...
Market anticipation grows over imminent competition between Eli Lilly and Novo Nordisk with Zepbound's FDA approval. Mounjaro's superior weight loss efficacy could positively impact Eli Lilly's market performance.
Eli Lilly's Mounjaro Three Times More Effective Than Ozempic for Weight Loss, Real-world Study Finds
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3557Followers
0Following
8390Visitors
Follow